IRWD - Ironwood Pharmaceuticals Inc Stock Price, Fair Value and News

6.83USD+0.20 (+3.02%)Delayed as of 15 May 2024, 09:56 am ET

Market Summary

USD6.83+0.20

Delayedas of 15 May 2024, 09:56 am

3.02%

IRWD Alerts

Big fall in Revenue (Y/Y)

Big fall in earnings (Y/Y)
Losses in recent quarter

IRWD Stock Price

View Fullscreen

IRWD RSI Chart

IRWD Valuation

Market Cap

1.1B

Price/Earnings (Trailing)

-1

Price/Sales (Trailing)

2.55

EV/EBITDA

-1.15

Price/Free Cashflow

7.13

IRWD Price/Sales (Trailing)

IRWD Profitability

Operating Margin

95.38%

EBT Margin

-243.98%

Return on Equity

318.32%

Return on Assets

-239.76%

Free Cashflow Yield

14.04%

IRWD Fundamentals

IRWD Revenue

Revenue (TTM)

413.6M

Rev. Growth (Yr)

-28.05%

Rev. Growth (Qtr)

-36.3%

IRWD Earnings

Earnings (TTM)

-1.1B

Earnings Growth (Yr)

-109.1%

Earnings Growth (Qtr)

-282.89%

Breaking Down IRWD Revenue

52 Week Range

6.8011.67

(Low)(High)

Last 7 days

-18.3%

Last 30 days

-15.9%

Last 90 days

-57.1%

Trailing 12 Months

-37.0%

How does IRWD drawdown profile look like?

IRWD Financial Health

Current Ratio

0.82

Debt/Equity

-0.6

Debt/Cashflow

0.75

IRWD Investor Care

Shares Dilution (1Y)

2.32%

Diluted EPS (TTM)

-6.79

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	413.6M	0	0	0
2023	417.1M	427.3M	432.4M	442.7M
2022	422.4M	415.6M	420.5M	410.6M
2021	398.4M	413.0M	413.3M	413.8M
2020	439.6M	426.8M	399.1M	389.5M
2019	343.0M	364.1M	436.0M	428.4M
2018	315.3M	331.3M	303.8M	343.4M
2017	260.1M	270.8M	291.5M	298.3M
2016	186.7M	213.3M	239.8M	274.0M
2015	90.8M	111.7M	134.3M	149.6M
2014	34.2M	31.4M	43.4M	76.4M
2013	118.4M	86.6M	54.7M	22.9M
2012	67.9M	71.2M	155.4M	150.2M
2011	45.3M	47.3M	50.5M	65.9M
2010	36.7M	39.1M	41.5M	43.9M
2009	0	0	0	34.3M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Ironwood Pharmaceuticals Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 15, 2024	denner alexander j	acquired	-	-	1,662	-
Mar 08, 2024	john minardo	acquired	-	-	32,752	chief legal officer
Mar 08, 2024	davis andrew	acquired	-	-	37,120	svp, chief business officer
Mar 08, 2024	shetzline michael	acquired	-	-	34,936	cmo,svp,head-res&drug
Mar 08, 2024	mccourt thomas a	acquired	-	-	120,298	chief executive officer
Mar 08, 2024	emany sravan kumar	acquired	-	-	37,120	svp, chief financial officer
Mar 06, 2024	duane jon r	bought	60,204	8.7	6,920	-
Mar 05, 2024	mccourt thomas a	acquired	-	-	264,876	chief executive officer
Mar 04, 2024	emany sravan kumar	bought	100,216	9.38	10,684	svp, chief financial officer
Feb 12, 2024	silver ronald	sold	-120,518	15.24	-7,908	principal accounting officer

Which funds bought or sold IRWD recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 13, 2024	UniSuper Management Pty Ltd	new	-	307,524	307,524	-%
May 13, 2024	ROYCE & ASSOCIATES LP	added	97.82	1,729,800	5,147,640	0.05%
May 13, 2024	Nuveen Asset Management, LLC	added	0.38	-4,952,910	16,054,600	-%
May 13, 2024	XPONANCE, INC.	added	0.52	-38,011	123,934	-%
May 13, 2024	NATIXIS	unchanged	-	-6.00	17.00	-%
May 13, 2024	Ethic Inc.	sold off	-100	-120,074	-	-%
May 13, 2024	Handelsbanken Fonder AB	unchanged	-	-130,000	417,000	-%
May 13, 2024	HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND	reduced	-6.16	-821,600	2,055,560	0.01%
May 13, 2024	GEODE CAPITAL MANAGEMENT, LLC	added	2.17	-7,828,980	27,415,400	-%
May 13, 2024	Rafferty Asset Management, LLC	added	45.04	836,954	8,865,200	0.03%

Are Funds Buying or Selling IRWD?

Are funds buying IRWD calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own IRWD

No. of Funds

Unveiling Ironwood Pharmaceuticals Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 09, 2024	lsv asset management	4.35%	6,793,701	SC 13G/A
Jan 25, 2024	state street corp	7.39%	11,532,088	SC 13G/A
Jan 22, 2024	blackrock inc.	16.6%	25,978,899	SC 13G/A
Jan 10, 2024	vanguard group inc	10.27%	16,033,545	SC 13G/A
Jul 05, 2023	westfield capital management co lp	-	0	SC 13G/A
May 10, 2023	wellington management group llp	0.00%	0	SC 13G/A
Feb 14, 2023	brown capital management llc	2.61%	3,997,045	SC 13G/A
Feb 10, 2023	lsv asset management	5.17%	7,926,397	SC 13G
Feb 09, 2023	vanguard group inc	9.60%	14,732,569	SC 13G/A
Feb 06, 2023	wellington management group llp	8.70%	13,340,377	SC 13G/A

Recent SEC filings of Ironwood Pharmaceuticals Inc

View All Filings

Date Filed	Form Type	Document
May 09, 2024	10-Q	Quarterly Report
May 09, 2024	8-K	Current Report
Apr 25, 2024	ARS	ARS
Apr 25, 2024	DEF 14A	DEF 14A
Apr 25, 2024	DEFA14A	DEFA14A
Mar 19, 2024	4	Insider Trading
Mar 12, 2024	4	Insider Trading
Mar 12, 2024	4	Insider Trading
Mar 12, 2024	4	Insider Trading
Mar 12, 2024	4	Insider Trading

Peers (Alternatives to Ironwood Pharmaceuticals Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
JNJ	364.3B	85.6B	2.61%	-5.13%	9.47	4.25	5.68%	202.39%
MRK	325.7B	61.4B	2.27%	10.50%	141.24	5.3	6.11%	-82.30%
AMGN	167.1B	29.5B	16.53%	34.63%	44.4	5.66	12.76%	-52.47%
PFE	160.8B	57.8B	9.74%	-23.63%	128.3	2.78	76.51%	-86.81%
GILD	84.3B	27.4B	-0.65%	-13.72%	173.91	3.07	1.51%	-91.32%
TEVA	19.4B	16.0B	28.50%	111.77%	-39.14	1.21	7.23%	71.10%
MID-CAP
ALKS	4.1B	1.7B	0.33%	-20.97%	9.54	2.4	54.01%	364.56%
PRGO	4.1B	4.6B	-0.23%	-11.63%	-536.25	0.91	-0.06%	94.55%
BHC	2.6B	9.0B	-18.61%	18.24%	-5.74	0.29	10.01%	-27.45%
AMPH	2.0B	676.2M	4.22%	-1.13%	13.06	2.99	30.38%	66.04%
SMALL-CAP
TLRY	1.6B	743.2M	14.29%	-14.40%	-4.57	2.17	24.65%	80.36%
TXMD	23.5M	1.3M	2.51%	-53.53%	-3.18	18.07	-98.14%	-104.71%
ACRX	17.3M	89.6M	-8.93%	29.11%	-1.22	0.19	287.27%	-129.41%
AGRX	2.5M	19.6M	5.56%	-92.00%	-0.17	0.13	80.00%	43.08%
ACOR	472.0K	115.7M	-50.00%	-97.38%	0	0	-2.22%	-352.48%

Ironwood Pharmaceuticals Inc News

Latest updates

Ironwood Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Income Statement (Quarterly)																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-36.3%	75.00	118	114	107	104	107	109	97.00	98.00	117	104	104	89.00	117	103	89.00	80.00	126	131	102	69.00
Costs and Expenses	-20.1%	64.00	80.00	74.00	1,191	44.00	39.00	40.00	42.00	40.00	61.00	39.00	39.00	43.00	65.00	58.00	57.00	67.00	77.00	65.00	81.00	86.00
Operating Expenses	-	-	-	-	-	44.00	-	40.00	42.00	40.00	-	39.00	39.00	43.00	-	-	-	-	-	-	-	-
S&GA Expenses	-2.7%	38.00	39.00	36.00	52.00	31.00	28.00	29.00	30.00	29.00	29.00	28.00	27.00	28.00	34.00	35.00	35.00	36.00	39.00	41.00	43.00	49.00
R&D Expenses	-27.6%	26.00	36.00	33.00	35.00	13.00	10.00	12.00	11.00	11.00	32.00	11.00	12.00	15.00	16.00	22.00	22.00	28.00	27.00	28.00	29.00	32.00
EBITDA Margin	-13.4%	-2.37*	-2.09*	-2.06*	-2.01*	0.65*	0.64*	0.58*	0.57*	0.58*	0.56*	0.56*	0.50*	-	-	-	-	-	-	-	-	-
Interest Expenses	-14.2%	7.00	8.00	10.00	2.00	2.00	2.00	2.00	2.00	2.00	8.00	8.00	8.00	8.00	8.00	7.00	7.00	7.00	7.00	10.00	9.00	10.00
Income Taxes	-71.7%	9.00	32.00	18.00	13.00	20.00	23.00	20.00	17.00	18.00	5.00	4.00	-336	0.00	1.00	1.00	-	-	-	-	-	-
Earnings Before Taxes	-83.7%	5.00	30.00	32.00	-1,076	66.00	72.00	70.00	54.00	56.00	46.00	60.00	54.00	40.00	45.00	36.00	25.00	3.00	48.00	21.00	-	-
EBT Margin	-13.9%	-2.44*	-2.14*	-2.10*	-2.03*	0.63*	0.61*	0.54*	0.52*	0.51*	0.48*	0.48*	0.42*	-	-	-	-	-	-	-	-	-
Net Income	-282.9%	-4.16	-1.09	15.00	-1,062	46.00	49.00	50.00	37.00	39.00	41.00	56.00	391	40.00	43.00	34.00	25.00	3.00	48.00	21.00	12.00	-59.28
Net Income Margin	-12.4%	-2.54*	-2.26*	-2.20*	-2.15*	0.44*	0.43*	0.40*	0.42*	1.25*	1.28*	1.28*	1.23*	-	-	-	-	-	-	-	-	-
Free Cashflow	26.1%	45.00	36.00	32.00	35.00	80.00	79.00	69.00	61.00	64.00	64.00	75.00	49.00	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-6.8%	439	471	524	603	1,155	1,101	1,040	976	1,083	1,127	1,079	1,007	599	559	492	444	404	403	334	316	324
Current Assets	-10.8%	208	233	254	318	866	781	699	618	710	745	695	620	538	496	433	374	334	307	258	221	202
Cash Equivalents	31.9%	122	92.00	110	175	740	656	574	504	593	620	574	493	438	365	308	253	231	179	139	99.00	119
Inventory	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.00	2.00	2.00	1.00
Net PPE	-5.3%	5.00	6.00	6.00	6.00	6.00	6.00	7.00	7.00	7.00	8.00	8.00	8.00	9.00	9.00	9.00	11.00	12.00	12.00	11.00	7.00	10.00
Goodwill	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.00	1.00	1.00	1.00
Current Liabilities	-8.6%	252	276	281	305	24.00	26.00	27.00	23.00	147	162	146	134	24.00	32.00	33.00	27.00	28.00	41.00	53.00	111	119
Long Term Debt	0.1%	198	198	198	198	397	396	396	395	395	337	333	329	436	430	425	419	413	408	403	274	270
LT Debt, Current	0.1%	200	200	199	199	-	-	-	-	121	117	115	113	-	-	-	-	-	-	-	-	-
LT Debt, Non Current	-100.0%	-	198	198	198	397	396	396	395	395	337	333	329	436	430	425	419	413	408	403	274	270
Shareholder's Equity	4.6%	-330	-346	-	-	707	652	591	533	518	606	580	512	110	63.00	6.00	-	-	-	-	-	-
Retained Earnings	-0.2%	-1,702	-1,698	-1,697	-1,712	-650	-696	-745	-795	-832	-937	-978	-1,034	-1,426	-1,466	-1,509	-1,543	-1,568	-1,572	-1,620	-1,640	-1,650
Additional Paid-In Capital	1.3%	1,373	1,355	1,375	1,367	1,357	1,349	1,336	1,328	1,350	1,543	1,559	1,546	1,536	1,529	1,515	1,507	1,497	1,479	1,467	1,421	1,413
Shares Outstanding	1.7%	159	156	156	156	155	154	155	153	158	162	162	162	-	-	-	-	-	-	-	-	-
Minority Interest	-	-	-	-2.46	-1.07	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	1,466	-	-	-	1,555	-	-	-	1,859	-	-	-	1,635	-	-	-	1,697	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	25.5%	44,985	35,834	32,459	34,963	80,171	79,182	69,092	61,365	64,124	64,568	75,065	48,568	73,694	51,513	53,632	20,088	43,603	27,580	34,767	-9,237	-42,385
Share Based Compensation	-3.7%	8,385	8,704	7,906	8,264	7,131	7,291	7,067	6,601	6,089	6,090	6,206	4,589	5,396	10,008	7,712	7,091	6,364	5,486	5,520	6,337	13,934
Cashflow From Investing	98.4%	-68.00	-4,188	-22,625	-999,492	-13.00	27.00	-66.00	-88.00	-9.00	-128	-	-	-	-28.00	-	-376	-1,438	-2,661	-3,077	-2,429	-2,977
Cashflow From Financing	69.4%	-15,555	-50,904	-74,988	399,071	3,981	2,806	797	-150,283	-90,873	-18,587	6,164	5,662	2,211	3,524	670	2,397	11,955	6,447	8,633	-7,500	-8,765
Buy Backs	-	-	-	-	32,900	90,500	-	1,505	32,896	90,489	-	-	-	-	-	-	-	-	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

IRWD Income Statement

2024-03-31

Condensed Consolidated Statements of Income (Loss) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenues:
Total revenues	$ 74,877	$ 104,061
Revenue from Contract with Customer, Product and Service	Collaborative arrangements revenue	Collaborative arrangements revenue
Costs and expenses:
Research and development	$ 25,815	$ 12,847
Selling, general and administrative	37,605	31,117
Restructuring expenses	437
Total costs and expenses	63,857	43,964
Income from operations	11,020	60,097
Other income (expense):
Interest expense and other financing costs	(7,231)	(1,527)
Interest and investment income	1,169	7,272
Gain on derivatives		19
Other income (expense), net	(6,062)	5,764
Income before income taxes	4,958	65,861
Income tax expense	(9,120)	(20,147)
Net income (loss)	$ (4,162)	$ 45,714
Net income (loss) per share - basic (in dollars per share)	$ (0.03)	$ 0.30
Net income (loss) per share - diluted (in dollars per share)	$ (0.03)	$ 0.25
Weighted average shares used in computing net income (loss) per share - basic (in shares)	157,700	154,452
Weighted average shares used in computing net income (loss) per share - diluted (in shares)	157,700	186,680

IRWD Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 121,540	$ 92,154
Accounts receivable, net	72,015	129,122
Prepaid expenses and other current assets	14,619	12,012
Total current assets	208,174	233,288
Property and equipment, net	5,288	5,585
Operating lease right-of-use assets	12,208	12,586
Intangible assets, net	3,478	3,682
Deferred tax assets	206,273	212,324
Other assets	3,398	3,608
Total assets	438,819	471,073
Current liabilities:
Accounts payable	6,222	7,830
Accrued research and development costs	11,880	21,331
Accrued expenses and other current liabilities	31,398	44,254
Current portion of operating lease liabilities	3,142	3,126
Current portion of convertible senior notes	199,800	199,560
Total current liabilities	252,442	276,101
Convertible senior notes, net of current portion	198,477	198,309
Operating lease obligations, net of current portion	14,004	14,543
Revolving credit facility	275,000	300,000
Other liabilities	29,414	28,415
Commitments and contingencies
Stockholders' equity (deficit):
Class A Common Stock, $0.001 par value, 500,000,000 shares authorized and 158,957,123 shares issued and outstanding at March 31, 2024 and 500,000,000 shares authorized and 156,354,238 shares issued and outstanding at December 31, 2023	159	156
Additional paid-in capital	1,373,022	1,355,195
Accumulated deficit	(1,702,777)	(1,698,615)
Accumulated other comprehensive loss	(922)	(3,031)
Total stockholders' deficit	(330,518)	(346,295)
Total liabilities and stockholders' deficit	$ 438,819	$ 471,073

About Ironwood Pharmaceuticals Inc

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.

CEO	Mr. Thomas A. McCourt
WEBSITE	ironwoodpharma.com
INDUSTRY	Pharmaceuticals
EMPLOYEES	219

Ironwood Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Ironwood Pharmaceuticals Inc? What does IRWD stand for in stocks?

IRWD is the stock ticker symbol of Ironwood Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Ironwood Pharmaceuticals Inc (IRWD)?

As of Tue May 14 2024, market cap of Ironwood Pharmaceuticals Inc is 1.05 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of IRWD stock?

You can check IRWD's fair value in chart for subscribers.

What is the fair value of IRWD stock?

You can check IRWD's fair value in chart for subscribers. The fair value of Ironwood Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Ironwood Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for IRWD so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Ironwood Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether IRWD is over valued or under valued. Whether Ironwood Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Ironwood Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for IRWD.

What is Ironwood Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue May 14 2024, IRWD's PE ratio (Price to Earnings) is -1 and Price to Sales (PS) ratio is 2.55. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. IRWD PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Ironwood Pharmaceuticals Inc's stock?

In the past 10 years, Ironwood Pharmaceuticals Inc has provided -0.055 (multiply by 100 for percentage) rate of return.